Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
37
ANIP Quote, Financials, Valuation and Earnings
Last price:
$77.96
Seasonality move
:
5.45%
Day range:
$76.69 - $78.35
52-week range:
$54.10 - $99.50
Dividend yield:
0%
P/E ratio:
47.90x
P/S ratio:
1.91x
P/B ratio:
3.47x
Volume:
363.6K
Avg. volume:
474.7K
1-year change:
30.19%
Market cap:
$1.8B
Revenue:
$614.4M
EPS (TTM):
$1.63
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ANIP
ANI Pharmaceuticals, Inc.
|
$231M | $1.98 | 11.21% | 141.43% | $110.50 |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$113M | $0.09 | 49.53% | -88.43% | $31.75 |
|
CAPR
Capricor Therapeutics, Inc.
|
-- | -$0.55 | -100% | -7.2% | $50.80 |
|
CRMD
CorMedix, Inc.
|
$127M | $0.81 | 178.58% | 96.01% | $14.86 |
|
CSTL
Castle Biosciences, Inc.
|
$80.3M | -$0.24 | -12.07% | -55.29% | $48.57 |
|
FOLD
Amicus Therapeutics, Inc.
|
$185M | $0.18 | 29.62% | 267.32% | $14.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ANIP
ANI Pharmaceuticals, Inc.
|
$78.10 | $110.50 | $1.8B | 47.90x | $0.00 | 0% | 1.91x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$27.95 | $31.75 | $3.4B | -- | $0.00 | 0% | 11.23x |
|
CAPR
Capricor Therapeutics, Inc.
|
$29.15 | $50.80 | $1.6B | -- | $0.00 | 0% | 118.88x |
|
CRMD
CorMedix, Inc.
|
$7.08 | $14.86 | $557.8M | 3.45x | $0.00 | 0% | 2.38x |
|
CSTL
Castle Biosciences, Inc.
|
$31.34 | $48.57 | $914.8M | 30.24x | $0.00 | 0% | 2.68x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.35 | $14.50 | $4.5B | -- | $0.00 | 0% | 7.34x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ANIP
ANI Pharmaceuticals, Inc.
|
55.53% | -0.779 | 30.7% | 2.40x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
41.85% | -0.523 | 5.02% | 3.07x |
|
CAPR
Capricor Therapeutics, Inc.
|
17.61% | -4.224 | 5.44% | 3.50x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.679 | 0.48% | 1.60x |
|
CSTL
Castle Biosciences, Inc.
|
7.37% | 0.721 | 5.59% | 6.09x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.293 | 18.22% | 1.91x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ANIP
ANI Pharmaceuticals, Inc.
|
$111.8M | $22.8M | 3.31% | 8.22% | 10.02% | $37.9M |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$90.5M | $8.5M | -15.75% | -29.4% | 8.59% | -$1.8M |
|
CAPR
Capricor Therapeutics, Inc.
|
-$494.7K | -$26.3M | -72.3% | -77.32% | -69.16% | -$23.7M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
CSTL
Castle Biosciences, Inc.
|
$61.5M | -$6.8M | -2.54% | -2.71% | -8.19% | $7.8M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
ANI Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns ANIP or ARQT?
Arcutis Biotherapeutics, Inc. has a net margin of 10.59% compared to ANI Pharmaceuticals, Inc.'s net margin of 7.47%. ANI Pharmaceuticals, Inc.'s return on equity of 8.22% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.
Company Gross Margin Earnings Per Share Invested Capital ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M -
What do Analysts Say About ANIP or ARQT?
ANI Pharmaceuticals, Inc. has a consensus price target of $110.50, signalling upside risk potential of 41.49%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.75 which suggests that it could grow by 13.6%. Given that ANI Pharmaceuticals, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe ANI Pharmaceuticals, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANIPANI Pharmaceuticals, Inc.4 1 0 ARQTArcutis Biotherapeutics, Inc.5 1 0 -
Is ANIP or ARQT More Risky?
ANI Pharmaceuticals, Inc. has a beta of 0.500, which suggesting that the stock is 50.037% less volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.702, suggesting its more volatile than the S&P 500 by 70.199%.
-
Which is a Better Dividend Stock ANIP or ARQT?
ANI Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals, Inc. pays 8.77% of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ANIP or ARQT?
ANI Pharmaceuticals, Inc. quarterly revenues are $227.8M, which are larger than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. ANI Pharmaceuticals, Inc.'s net income of $24.1M is higher than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, ANI Pharmaceuticals, Inc.'s price-to-earnings ratio is 47.90x while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals, Inc. is 1.91x versus 11.23x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANIPANI Pharmaceuticals, Inc.1.91x 47.90x $227.8M $24.1M ARQTArcutis Biotherapeutics, Inc.11.23x -- $99.2M $7.4M
-
Which has Higher Returns ANIP or CAPR?
Capricor Therapeutics, Inc. has a net margin of 10.59% compared to ANI Pharmaceuticals, Inc.'s net margin of -63.94%. ANI Pharmaceuticals, Inc.'s return on equity of 8.22% beat Capricor Therapeutics, Inc.'s return on equity of -77.32%.
Company Gross Margin Earnings Per Share Invested Capital ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B CAPRCapricor Therapeutics, Inc.-- -$0.54 $101.8M -
What do Analysts Say About ANIP or CAPR?
ANI Pharmaceuticals, Inc. has a consensus price target of $110.50, signalling upside risk potential of 41.49%. On the other hand Capricor Therapeutics, Inc. has an analysts' consensus of $50.80 which suggests that it could grow by 74.27%. Given that Capricor Therapeutics, Inc. has higher upside potential than ANI Pharmaceuticals, Inc., analysts believe Capricor Therapeutics, Inc. is more attractive than ANI Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANIPANI Pharmaceuticals, Inc.4 1 0 CAPRCapricor Therapeutics, Inc.8 0 0 -
Is ANIP or CAPR More Risky?
ANI Pharmaceuticals, Inc. has a beta of 0.500, which suggesting that the stock is 50.037% less volatile than S&P 500. In comparison Capricor Therapeutics, Inc. has a beta of 0.377, suggesting its less volatile than the S&P 500 by 62.266%.
-
Which is a Better Dividend Stock ANIP or CAPR?
ANI Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Capricor Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals, Inc. pays 8.77% of its earnings as a dividend. Capricor Therapeutics, Inc. pays out -- of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ANIP or CAPR?
ANI Pharmaceuticals, Inc. quarterly revenues are $227.8M, which are larger than Capricor Therapeutics, Inc. quarterly revenues of --. ANI Pharmaceuticals, Inc.'s net income of $24.1M is higher than Capricor Therapeutics, Inc.'s net income of -$24.6M. Notably, ANI Pharmaceuticals, Inc.'s price-to-earnings ratio is 47.90x while Capricor Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals, Inc. is 1.91x versus 118.88x for Capricor Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANIPANI Pharmaceuticals, Inc.1.91x 47.90x $227.8M $24.1M CAPRCapricor Therapeutics, Inc.118.88x -- -- -$24.6M
-
Which has Higher Returns ANIP or CRMD?
CorMedix, Inc. has a net margin of 10.59% compared to ANI Pharmaceuticals, Inc.'s net margin of 49.9%. ANI Pharmaceuticals, Inc.'s return on equity of 8.22% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About ANIP or CRMD?
ANI Pharmaceuticals, Inc. has a consensus price target of $110.50, signalling upside risk potential of 41.49%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 109.85%. Given that CorMedix, Inc. has higher upside potential than ANI Pharmaceuticals, Inc., analysts believe CorMedix, Inc. is more attractive than ANI Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANIPANI Pharmaceuticals, Inc.4 1 0 CRMDCorMedix, Inc.4 0 0 -
Is ANIP or CRMD More Risky?
ANI Pharmaceuticals, Inc. has a beta of 0.500, which suggesting that the stock is 50.037% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.76%.
-
Which is a Better Dividend Stock ANIP or CRMD?
ANI Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals, Inc. pays 8.77% of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ANIP or CRMD?
ANI Pharmaceuticals, Inc. quarterly revenues are $227.8M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. ANI Pharmaceuticals, Inc.'s net income of $24.1M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, ANI Pharmaceuticals, Inc.'s price-to-earnings ratio is 47.90x while CorMedix, Inc.'s PE ratio is 3.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals, Inc. is 1.91x versus 2.38x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANIPANI Pharmaceuticals, Inc.1.91x 47.90x $227.8M $24.1M CRMDCorMedix, Inc.2.38x 3.45x $104.3M $108.6M
-
Which has Higher Returns ANIP or CSTL?
Castle Biosciences, Inc. has a net margin of 10.59% compared to ANI Pharmaceuticals, Inc.'s net margin of -0.6%. ANI Pharmaceuticals, Inc.'s return on equity of 8.22% beat Castle Biosciences, Inc.'s return on equity of -2.71%.
Company Gross Margin Earnings Per Share Invested Capital ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B CSTLCastle Biosciences, Inc.74.09% -$0.02 $504.2M -
What do Analysts Say About ANIP or CSTL?
ANI Pharmaceuticals, Inc. has a consensus price target of $110.50, signalling upside risk potential of 41.49%. On the other hand Castle Biosciences, Inc. has an analysts' consensus of $48.57 which suggests that it could grow by 54.98%. Given that Castle Biosciences, Inc. has higher upside potential than ANI Pharmaceuticals, Inc., analysts believe Castle Biosciences, Inc. is more attractive than ANI Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANIPANI Pharmaceuticals, Inc.4 1 0 CSTLCastle Biosciences, Inc.8 0 0 -
Is ANIP or CSTL More Risky?
ANI Pharmaceuticals, Inc. has a beta of 0.500, which suggesting that the stock is 50.037% less volatile than S&P 500. In comparison Castle Biosciences, Inc. has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.16%.
-
Which is a Better Dividend Stock ANIP or CSTL?
ANI Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Castle Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals, Inc. pays 8.77% of its earnings as a dividend. Castle Biosciences, Inc. pays out -- of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ANIP or CSTL?
ANI Pharmaceuticals, Inc. quarterly revenues are $227.8M, which are larger than Castle Biosciences, Inc. quarterly revenues of $83M. ANI Pharmaceuticals, Inc.'s net income of $24.1M is higher than Castle Biosciences, Inc.'s net income of -$501K. Notably, ANI Pharmaceuticals, Inc.'s price-to-earnings ratio is 47.90x while Castle Biosciences, Inc.'s PE ratio is 30.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals, Inc. is 1.91x versus 2.68x for Castle Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANIPANI Pharmaceuticals, Inc.1.91x 47.90x $227.8M $24.1M CSTLCastle Biosciences, Inc.2.68x 30.24x $83M -$501K
-
Which has Higher Returns ANIP or FOLD?
Amicus Therapeutics, Inc. has a net margin of 10.59% compared to ANI Pharmaceuticals, Inc.'s net margin of 10.24%. ANI Pharmaceuticals, Inc.'s return on equity of 8.22% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About ANIP or FOLD?
ANI Pharmaceuticals, Inc. has a consensus price target of $110.50, signalling upside risk potential of 41.49%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.05%. Given that ANI Pharmaceuticals, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe ANI Pharmaceuticals, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANIPANI Pharmaceuticals, Inc.4 1 0 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is ANIP or FOLD More Risky?
ANI Pharmaceuticals, Inc. has a beta of 0.500, which suggesting that the stock is 50.037% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.857%.
-
Which is a Better Dividend Stock ANIP or FOLD?
ANI Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals, Inc. pays 8.77% of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ANIP or FOLD?
ANI Pharmaceuticals, Inc. quarterly revenues are $227.8M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. ANI Pharmaceuticals, Inc.'s net income of $24.1M is higher than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, ANI Pharmaceuticals, Inc.'s price-to-earnings ratio is 47.90x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals, Inc. is 1.91x versus 7.34x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANIPANI Pharmaceuticals, Inc.1.91x 47.90x $227.8M $24.1M FOLDAmicus Therapeutics, Inc.7.34x -- $169.1M $17.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
23
CAR alert for Feb 20
Avis Budget Group, Inc. [CAR] is down 0.3% over the past day.
Buy
75
HYMC alert for Feb 20
Hycroft Mining Holding Corp. [HYMC] is down 2.47% over the past day.
Sell
1
EPAM alert for Feb 20
EPAM Systems, Inc. [EPAM] is down 0.11% over the past day.
